US Patent Issued to TEVA PHARMACEUTICALS AUSTRALIA on March 25 for "Anti-CD47 combination therapy" (California Inventors)

ALEXANDRIA, Va., March 26 -- United States Patent no. 12,258,401, issued on March 25, was assigned to TEVA PHARMACEUTICALS AUSTRALIA PTY LTD (New South Wales, Australia).

"Anti-CD47 combination therapy" was invented by Sarah Lee Pogue (Redwood City, Calif.), David Scofield Wilson Jr. (Redwood City, Calif.) and Tetsuya Taura (Redwood City, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides a combination therapy for treating a tumor in a subject. The combination comprises two elements. The first is a polypeptide construct comprising an attenuated Type I interferon (IFN) linked to an antibody which binds to a cell surface-associated antigen expressed on the tumour cell and comp...